CRPGF Hits New Highs
CNRP Mining, Inc. (CRPGF) has been on our radar for awhile now. Since announcing the initial LOI to bring on a new CBD asset to the company, we’ve followed along with new developments to this emerging story. The company’s latest announcement could have signaled what we’ve been waiting for. The company announced that further to the its press release on July 21, 2017 and in conjunction with its non-binding letter of intent to acquire X-SRAYS, it has advanced USD $300,000 to X-SPRAYS. Furthermore, (CRPGF) said that it anticipates signing a definitive agreement for the acquisition in September 2017.Based on what was announced, we think a lot more people are starting to pay closer attention. So if you have yet to read up on this company, click the link below for more details.
Tetra Bio-Pharma Inc. (TBPMF) Strengthens its Management Team in Preparation for the Initiation of its Commercial Activities
Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP)(TBPMF) today announced that it has strengthened its management team in preparation for the initiation of its commercial activities with the appointments of Dr. Anne-Sophie Courtois to the position of Vice President, Marketing effective immediately and Mr. Bernard Lessard to the position of Chief Financial Officer (CFO), effective September 18, 2017. Mr. Lessard will be replacing Mr. Sabino Di Paola as CFO of the corporation.
GT Biopharma (OXISD) Heads Higher On Monday (8-28)
GT Biopharma Inc. (formerly known as Oxis International, Inc.) rallied to highs of $19.25 on Monday (8-28) to continue the 4-day rally it has seen since last Wednesday (8-23) Excitement is still building around this latest acquisition of Georgetown Translational Pharmaceuticals. The new company can now provide sufficient funding for the continuing development of its highly sought after oncology assets and GTP’s assets, which include leading candidate, Pain Brake. According to the company this oncology asset is expected to be submitted to the FDA as a New Drug Application in 15 to 18 months, which would allow GT Biopharma, Inc. to start marketing the drug shortly thereafter. If you haven’t done so yet, take a look at (OXISD).